, Tracking Stock Market Picks
Enter Symbol:
ImmunoCellular Therapeutics Ltd (IMUC) [hlAlert]

3 Months Gains
down 87.61 %

ImmunoCellular Therapeutics Ltd (IMUC) rated Buy with price target $18 by Maxim Group

Posted on: Thursday,  Sep 6, 2012  8:25 AM ET by Maxim Group

ImmunoCellular Therapeutics Ltd (AMEX: IMUC)
rated Buy with price target $18 by Maxim Group.

ImmunoCellular Therapeutics, Ltd. is a development stage company that is seeking to develop and commercialize therapeutics to fight cancer using the immune system. The Company?s product candidate portfolio includes peptide based cellular immunotherapies targeting cancer stem cells, cellular immunotherapies targeting cancer antigens and monoclonal antibodies to diagnose and treat different cancers. As of December 31, 2008, the products under development include ICT-121, ICT-107, ICT-109, ICT-037, ICT-69 and ICT-Diagnostic-SCLC. In February 2008, the Company acquired certain monoclonal antibody related technology owned by Molecular Discoveries LLC (Molecular Discoveries).

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/6/2012 8:25 AM Buy
3.23 18.00
as of 12/31/2012
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy